International Clinical Trial: A Prospective, Single-Arm, Open-Label, Single-Center Clinical Study Evaluating the Efficacy and Safety of Regorafenib Combined with Epacadostat, Tislelizumab, and TACE as First-Line Treatment for Unresectable, Intermediate-to-Advanced Hepatocellular Carcinoma

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121995) titled 'A Prospective, Single-Arm, Open-Label, Single-Center Clinical Study Evaluating the Efficacy and Safety of Regorafenib Combined with Epacadostat, Tislelizumab, and TACE as First-Line Treatment for Unresectable, Intermediate-to-Advanced Hepatocellular Carcinoma' on April 8.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Henan Medical University

Condition: Hepatocellular Carcinoma

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-04-20

Target Sample Size: Experimental Group:45;

Countries of Recruitment: China

To k...